<SEC-DOCUMENT>0001193125-13-005264.txt : 20130107
<SEC-HEADER>0001193125-13-005264.hdr.sgml : 20130107
<ACCEPTANCE-DATETIME>20130107160007
ACCESSION NUMBER:		0001193125-13-005264
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130107
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130107
DATE AS OF CHANGE:		20130107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORTHOFIX INTERNATIONAL N V
		CENTRAL INDEX KEY:			0000884624
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19961
		FILM NUMBER:		13515327

	BUSINESS ADDRESS:	
		STREET 1:		7 ABRAHAM DE VEERSTRAAT
		STREET 2:		CURACAO
		CITY:			NETHERLANDS ANTILLES
		STATE:			P8
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d462460d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, DC 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): January&nbsp;7, 2013 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Orthofix International N.V. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of Registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Netherlands Antilles</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-19961</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="31%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7 Abraham de Veerstraat</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Curacao</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Netherlands Antilles</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: 011-59-99-465-8525 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( <I>see</I> General Instruction
A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;2.02.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations and Financial Condition </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;7, 2013, Orthofix International N.V. issued a press release announcing its unaudited preliminary results for the fourth quarter and year ending December&nbsp;31, 2012 . A copy of the press
release is furnished herewith as Exhibit 99.1 and attached hereto. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c)&nbsp;Exhibits </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press release of Orthofix International N.V. dated January&nbsp;7, 2013. </FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">ORTHOFIX INTERNATIONAL N.V.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: January&nbsp;7, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Emily V. Buxton</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Emily V. Buxton</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interim Chief Financial Officer</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d462460dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g462460g28k07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Orthofix International Provides Preliminary 2012 Results </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">LEWISVILLE, Texas &#150; January&nbsp;7, 2013 (BUSINESS WIRE) &#150; Orthofix International N.V., (NASDAQ:OFIX) (the Company) provided
today&nbsp;preliminary unaudited results for the fourth quarter, and year ending December&nbsp;31, 2012. The Company anticipates net sales to be approximately $112 million and full year 2012 net sales from continuing operations to be approximately
$462 million. The negative impact from foreign currency translation is expected to be approximately $10 million for the full year 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Company expects fourth quarter 2012 adjusted earnings from continuing operations per share to be between $0.78 and $0.83. For the full year 2012, adjusted earnings from continuing operations per share are expected to be between $3.01 and $3.06.
These sales and earnings results are preliminary and unaudited therefore are subject to change. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Despite the strong revenue increase in our
U.S. Spine Repair Implants and Regenerative Biologics business and an increase in our U.S. Orthopedic Repair business, the fourth quarter revenue was negatively impacted in international markets by regulatory and macroeconomic conditions. In
addition, the Company&#146;s Spine Regenerative Stimulation business was negatively impacted in the second half of the year by sales force turnover as we initially implemented our Corporate Integrity Agreement in June 2012. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Vaters, President and Chief Executive Officer, stated, &#147;While I am pleased with our preliminary earnings, I am disappointed in the
preliminary fourth quarter revenue. The international markets have presented many challenges in the latter part of 2012 and especially during the fourth quarter. These included general market and regulatory conditions in both the Spine and
Orthopedic businesses, mandatory price reductions for public hospitals in Italy, cancellation of reimbursement by the government on Physio-Stim in France, and a delay of surgeries by government hospitals and insurance providers. Despite top line
weakness in the fourth quarter, 2012 was a transformative year for Orthofix as we accomplished significant objectives by finalizing the three major legal matters, achieving our operating margin expansion goals, and improving the Company&#146;s
financial profile to enable investment in product pipeline and inorganic activities to drive future growth.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company will be
reporting final 2012 financial results along with 2013 guidance after the market close Thursday, February&nbsp;21, 2013. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Forward-Looking Statements:</U></B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This communication contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which may include, but are not limited to,
statements concerning the projections, financial condition, results of operations and businesses of Orthofix and its subsidiaries and are based on management&#146;s current expectations and estimates and involve risks and uncertainties that could
cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The forward-looking
statements in this release do not constitute guarantees or promises of future performance. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The
Company undertakes no obligation to update or revise the information contained in this press release (which contains information current as of the date hereof, whether as a result of new information, future events or circumstances, or otherwise.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>About Orthofix: </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Orthofix International N.V. is a diversified, global medical device company focused on developing and delivering innovative repair and regenerative
solutions to the spine and orthopedic markets. Orthofix&#146;s products are widely distributed around the world to orthopedic surgeons and patients via Orthofix&#146;s sales representatives and its subsidiaries, and via collaborations with other
leading orthopedic product companies. In addition, Orthofix is collaborating on R&amp;D activities with leading research and clinical organizations such as the Musculoskeletal Transplant Foundation, the Orthopedic Research and Education Foundation,
and Texas Scottish Rite Hospital for Children. For more information about Orthofix, please visit www.orthofix.com. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Contact</U>:</B>
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark Quick </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director of Investor
Relations and Business Development </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>markquick@orthofix.com</U> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">214-937-2924 </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Source</U></B>: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Orthofix International N.V. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g462460g28k07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g462460g28k07.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!``9<#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:HKFY@LX
M&GN9DAB099W;`%2,"5(4X/8D9K#U#PCIVKN'U22YNV'0/,55?HJX`JHJ-_>9
M,G)+W4<UK_Q0ABW6^AQ><_3[1*,(/H.I_'%>>W^K:AJDS2WUY-.S'.&8X'T'
M05Z-??#+1[V%Y-'O7A=25P7\R/(['N/SKSW6-%O]"O3:W\)C;JK#E7'J#WKV
M,,Z&T-_/<\7%*OO/;RV*L%S<6LGF6T\L+_WHW*G]*Z_P_P#$G4;"18=5)O;;
MH7_Y:I[Y_B_'\ZXNBNF=.%16DCEIU9TW>+/H>QOK;4K..[LYEFAD&59?\]:L
M5XQX%\4/H.JK;3N?L%TP60'I&W9A_7_ZU>S5X=>BZ4K=#WL/75:%^HM%%(2`
M"2<`=36!T"T5S6I_$/PEI#M'=:Y;>8O5(B9"/^^<XK&/QI\%@X%W<GW%LU`'
M?45P]M\8?!5P^TZE)#[RV[@?H#74:5KVD:W'YFEZE;78'412`D?4=10!H444
M4`%%96I^)]"T5MNI:O:6K_W))0&_+K6.?BEX)!(.OP\>D<A_]EH`ZVBN37XI
M>"68`:_#D^L<@_\`9:V],\0:-K0SIFIVMWCJ(I0Q'U'6@#1HK&USQ=H/AJ6*
M+6-12T>92T89&.X#KT!K+_X6GX(_Z#\7_?J3_P")H`ZVBN2_X6GX(_Z#\7_?
MJ3_XFC_A:?@C_H/Q?]^I/_B:`.MHKDO^%I^"/^@_%_WZD_\`B:O:1XX\-:]=
M/:Z7JL=S-'&9614<848R>0/44`;]%<E_PM/P1_T'X?\`OU)_\370Z7JMCK6G
M1:AIUPMQ:S9V2*"`V"0>O/4&@"Y1165KGB?1O#4<,FL7R6BSDB,LK'<1UZ`^
MM`&K17-:=\0_">JW\-A8ZS'-<SMMCC$;@L?Q7%=+0`45EZMXET30AG5=4MK0
MD9"22#<?HO4US,_QD\%0N4&H32X[QV[D?J!0!W5%<$GQH\%LP!O+E?<VS8K<
MTKQYX5UEUCL=;M7D;I&[>6Q^@;&:`.AHHHH`**K7NHV.FP^=?7D%K'_>FD"#
M]:P)OB7X+MVVOX@M2?\`8W/_`.@@T`=117)?\+3\$?\`0?B_[]2?_$T?\+3\
M$?\`0?B_[]2?_$T`=;16"/&_ALZ&=;&JQ_V>)?),^Q\;_3&,_I5`?%+P22`-
M?AR?^F4G_P`30!UM%8>M>,_#WAZ>*'5M16U>9-\>Z)R&'L0"*HP?$SP9<W$<
M$6O0&21@JAD=02>G)7`H`ZJBDI:`"BN8O/B1X/L+R6TN==@2:%BCJ$=L$=1D
M`BI]+\=>&=:FDBT[58YVAC,DA\MU5%'4EB``/J:`.@HK.M-?TR^N%@@N3YD@
M+1AXW3S`.NTL!N_#-%`%77?%ND^'T(NI]\^/EMXOF<_X?C7F?B#Q]JVM;H87
M-E:GCRXF^9A_M-_A7-2RO//)-(Q9Y&+,Q[DTRO<HX6%/5ZL\&MC*E31:(]C^
M&K`^#H0.TL@/UW5M:[H=IX@TQ[*[7KS'(!\T;=B*Y'X3WX?3KW3V;YHI1*H]
MF&#^H_6O0*\NO>%9M=SU</:=!)[6/GK4M.N-)U&>PNEVRPM@^A'8CV(JK7IG
MQ4T97MK?68EP\9\F8@=5/W3^!X_&O,Z]FA4]I!2/$KTO95'$",U[;X%U9M6\
M+6TDK;IH,PR$]25Z'\L5XE7I7PEG)@U.W/0.CC\00?Y"L,;&]*_8WP,VJMNY
MZ&S*B%W8*JC))/`%?.7Q#^)>H>)]0FLM/N'M](C8JB(=IG_VF/<'L.E>U?$2
M\DL?A_K,\1(?[,4!';<0O]:^6*\4]TWO"?@S5_&-\UOID2B./!FN)#B.,'U/
M<^PKTVU_9_MA$/M>ORM)W\J``#\S78_"K3(=-^'NFF)0'ND-Q*W]YF/^&!^%
M=A0!X5KGP'U&TMWGT;4X[XJ,^1+'Y;M[`Y()^N*\QBFO]&U'?%)/9WEN^,J2
MCHPZCVK[#KYX^-^F16/CA+F)57[;;+*X'=@2I/Y`4`>C?"KX@R>+;&73]2*_
MVG:*&+@8\Y.F['J#P?J*POB_\1+W2[K_`(1S1IS!+L#75PAPRYZ(I[<<D^XK
M@_A->26GQ&TP(<"<O$X]05/]0*S?'UPUUX\UJ5LY^V.O/HIVC^5`&9INF:EX
M@U-+.P@EN[N8Y"CDGU))Z#W->C6?P$UV:)7N]4LK9CU10TA'X\"LSX8^.-"\
M%)?3:A9W,UW<E51X54[4';DCJ?Y"N]_X7SX:_P"@?J7_`'PG_P`50!R-]\!_
M$%O;M)::A97;J,B/YD+?3(Q7F\4MWIE]OADDMKJW?`9&*LC`^HKVO4/C[IBV
M[C3='NI)L?(9V5%!]\$FO$II9;V\DE8;YIY"Q"CJQ/8?4T`>OKX>U#XQ>&M)
MU6348K6ZL5DMK@O$3YC`@AACID8S[U7_`.&?]0_Z#]M_WX;_`!KO_A9X>NO#
MG@BWMKY#'<W#M</&>J;L8!]\`9KL:`/E;QOX.F\%:M#I\]Y'=-+")=Z(5`Y(
MQS]*K^$/#4OBWQ!%I$-REL\B,PD=2P&T9Z"NS^//_(X6?_7DO_H;5F?!C_DH
M]I_UQE_]`-`'0_\`#/\`J'_0?MO^_#?XUT7@KX6W7@O4[O4Y]4ANE>RDAV)$
M5()(.<D_[->G5#>?\>4__7-OY4`?'+?>/UKZ:^$G_)--)^DO_HUZ^96^\?K7
MIGA+XQ-X7\-6FC#1!<_9MW[W[1MW;F+=-I]:`/H"O(?V@?\`D&Z+_P!=I?Y+
M57_AH)O^A<'_`(%__8UR/C_XC'QS;64)TP6?V5V;/G;]V0!Z#TH`H_#/_DHN
MB_\`7Q_[*:]5^+/Q&N/#@31-'D"7\R;YIAR84/0#_:/Z#ZUY5\,_^2BZ+_U\
M?^RFH/']Y)?>/-:FD))%V\8SV"G:/T%`&1%%?ZUJ211B:\O+E\*,EGD8UZGH
MWP#O)H%EUG5TM789,-O'YA7ZL2!^6:@^`FF0W&O:CJ4B!I+2%4BS_"7)R?R7
M'XFO=J`/'+S]G^'RB;'7W$@Z">`$'\0>*\N\3>%=5\):G]AU2$(S#=%*ARDJ
M^JG^G45]:5Y]\:]-BO/`4ETR`RV4R2(W<`G:1^.?TH`\_P#AC\3;W1]2M]&U
M>Y>?3)V$:/(V6MV/0@_W<]1VZUZ]X[\5IX/\,3ZEM5[AB(K>-NC2'IGV`!/X
M5\K=*]1^+6K37_A;P@)"<SV?VA^>K%$']30!YYJFKZEK^H-=ZC=2W=Q(>K'.
M/8#L/85W.B_!#Q)J=JEQ>S6^FJXR(Y<M(![@=/IFN-\,:I::+XDLM3O;5KJ&
MUD\PQ*0"Q`^7KZ'!_"O7/^&@--_Z`5U_W^7_``H`S1^S]=8&?$4.>^+4_P#Q
M5+_PS]<_]#%%_P"`I_\`BJT?^&@--_Z`5U_W^7_"M_P9\5+/QEK9TN#3)[9Q
M"TN]Y`PP"!CCZT`<KXR\*/X-^#CZ5)=K=G^T5E\Q4V#GMC)]*\;A_P!<G^\/
MYU]$?&[_`))\W_7W%_6OG>'_`%R?[P_G0!]6^(O"^G>+?#W]FZ@G5`8I@/FA
M?'##_#O7S/XG\,ZCX3UF33=1CPR\QR@?+*G9E_SQ7UC!_P`>\?\`N#^58?C'
MPAI_C'1FL;Q=DJ9:WG`^:)O7W'J.]`'GWPE^)9N!#X:UR?\`>@!;.Y<_?':-
MCZ^A[]/2KOQ8^)0TB*3P_HL_^GR#%S.A_P!0I_A!_O']/KT\8US1;_PSK4VF
M7R^7<V[#E&X(ZA@?<<U!96EWK.JPVD)\VZNY0BF1\;F8]23[]Z`+&@:#J'B;
M6(M,TZ(R3RG))Z(O=F/8"OHBP\%6OA7PE'8Z?`;ITGBGO"%^>ZVL"PQWX'"^
MV.]6O`O@>R\%:0((MLU[,`;FYQRY]!Z*.P_&NHH`\AM-#O+M+NVLI?M5Y=IF
M)XPR"V;SF=O,)`Y*$*">?F*XQS17KU%`'SWJMH;#6+RS(QY,SH/H#Q^E5*[?
MXGZ,;36H]4C7]U>+AR!TD4?U&/R-<17T5*?/!2/FJT/9U'$VO">N?\(_K\%V
MY/D-^[G`_N'O^!P?PKW-'62-9$8,C`%6!X(/>OG*N_\``7C=+)4T?59=L'2W
MG8\)_LM[>A[5R8R@YKGCNCLP6(4'R2V9W7BFS%_X8U&W(SF!F'U`R/U%>##I
M7T-?LO\`9ERQ.5\ECD'MM-?/(Z"IP#]V2*S%+FBPKTGX20-Y6IW!SM+(@^H!
M)_F*\VKV[P1HS:+X9@AE7;/-F:4>A;H/P&*UQLTJ5NYC@8.56_8?XXTV35_!
M.KV,*[I9+9BBCNR_,!^8KY1K[,KQ'XB?""\^W3:QX:A\^&9B\MDO#(QZE/4>
MW4=J\4]T[/X0:];ZMX&M;19!]IT[,$J9Y`R2I^A'\C7=U\CV&HZWX3U3S[62
MYTZ\CX(92I(]&4]1[$5V]K\=O$\,06>TT^X8?QM&RD_DV*`/H&OFWXP:]!KG
MC>1+6020V,0MPZG(9@26Q^)Q^%1Z[\7/%FN6SVINH[*"0$,MJFTL/3<23^1%
M8>@^$->\2SK'IFG32J3@S,NV-?JQXH`WO@]ILM_\0[.5%.RS1YY".PVE1^K"
ML'QG_P`CKK7_`%_3?^AFOH;X?^!+;P3I31[UGOKC!N)P,`XZ*OL/UKYW\8.)
M/&>M,.GV^;_T,T`=C\,OAQI7C32+R[U"YNX7@G$:B!E`(V@\Y!]:[*3X"^'3
M&PCU+45<@[2S(0#VR-O-1?`+_D6]3_Z_!_Z`*]6H`^1-?T*^\-ZS/I>H1[)H
M6ZCHZ]F'J#7J7P3O?#-PYLI],MHM<ART5PXW-,O^SGHP]NWXUVOQ)\"1>,M&
MWVZJFJ6JDV\AXWCNA/H>WH?QKYPBEO=&U-9(VDM+RTEX/W6C=3_C0!]AT5R/
MP\\=6_C/1@SE(]2MP%N81QG_`&U']T_H>*ZZ@#P'X\_\CA9_]>2_^AM69\&/
M^2CVG_7&7_T`UI_'D_\`%8V8_P"G%?\`T-JS/@Q_R4>S_P"N,O\`Z`:`/I&H
M;S_CRG_ZYM_*IJAO/^/*?_KFW\J`/CEOO'ZU[C\//AMX5U[P1I^IZCI[2W4X
MD\QQ.ZYQ(P'`..@%>''[Q^M?3/PD.?AGI/TE_P#1KT`1_P#"G_!'_0*?_P`"
M9/\`&O._B]X+T'PK9:9)H]HT#7$DBR$RL^0`,=2?6O>Z\A_:!_Y!NB_]=I?Y
M+0!YS\,_^2BZ+_U\?^RFD^).FR:7X_U:)T*K+.9T/JK_`#9_4C\*7X:?\E%T
M7_KX_P#937MOQ'^'D/C2R2XMG6#5+92(I&^[(O78W]#V_&@#S;X':[!IOBBY
MTVY<(-1B"Q$G`,BG('X@FOH"ODC6/#>N>&[KR]2T^XM'1OEDVG:2.ZL.#^!K
MJ-'^,OBW2H$@EF@OXT&`;I"7Q_O`@G\<T`?1]>9_''7;>R\*)HXD!N;^53L!
MY$:G))_$`?GZ5P][\<_%-Q$4MX+&T)&-Z1%B/IN)'Z5Q$KZUXIU5IG%UJ5[,
M>2%+L?RZ#]*`,^-'ED6-%+.Y`51U)->E_&*Q;2[3PK8-]ZVT[RC]5V@_RKH/
MAK\);C3KZ'7?$<:I+"=]O9Y#%6[,YZ9'8>OY5G_M`?\`(5T;_KA)_P"A"@#A
M?`.C67B#QG8:7J",]M.7WA&VDX0D<_45[9_PI;P7_P`^MU_X$M7D/PF/_%RM
M)_WI/_1;5].4`<#_`,*6\%_\^MU_X$M6KX<^'7AWPMJ9U'2X)DG,9CR\Q8;2
M03P?H*ZFB@#SWXW?\D^;_K[B_K7SO#_KD_WA_.OHCXW?\D^;_K[B_K7SO%Q,
MA/\`>%`'V-!_Q[Q_[@_E7&?$7XBVO@VR-M:E)]6G7]U$>1$/[[?T'>F^//B'
M:>#=(2"!DGU::(>3#G/EC'WW]O0=Z^=YIM0UW5FEE:6\OKN3D_>:1CVH`EAB
MU3Q/K@C3S;W4+V7J3EG8]2?;^0J7Q%X<U+PIK#Z=J,>R9,,CH3M=>S*?\]*]
M]^&OP\A\'Z?]KO%635[A?WK]1"O]Q?ZGO6GX[\%6GC31&MI-L5Y#EK6XQ]QO
M0_[)[_GVH`Y+X5?$T:Q'%H&MS`7Z#;;SN?\`CX']T_[7\_KU]4KX^O[&^T35
M);.[C>VN[63##."K#H0?U!KW?X7?$Q/$4":-K$P758UQ'(W`N5'_`+-ZCOU]
M:`/2J***`,[7M&@U[2)M/GX#C*/W1AT->%ZEIUUI-_+8WD9CFB.#Z$=B/4&O
MH6L;Q%X7T_Q);".[4I,@_=SI]Y/\1[5V8;$>R=I;'%BL-[57CN>$UK:)X9U7
MQ!)BRMCY6<-/)\L:_CW^@KT+1/ACIUC+YVI3&_<'Y4V[8Q]1W_E7:(D<$02-
M5CC0<*HP%%=57'):4]3DHX!O6IH<9?6DO@[P!>03ZE+=R2)Y4>_[J%N,+WQR
M3U[5Y.B-(ZQQJSNQPJJ,D_A7JWB#2-3\;:C%#$39Z1;'(FD'S3-W95[CL"?>
MM[0O"FD^'T'V2W#3X^:>3YG/X]OPJ*>(C2@W+63-*F'E6FE'2*.-\&>`+D7<
M>I:U#Y4<1#16S?>9NQ8=@/2O3***X:M6565Y'=1HQI1Y8A11161L5[JPL[Y=
MMY:07"^DL8?^=9;^"?"LC%G\.:82>I-JG^%;E%`&3;>%/#MFVZVT+3XCZI;(
M#_*M555%"JH51P`!@"EHH`*IOI.FR.SOI]JS,<EC"I)/KTJY10!#;VMM:*5M
MK>*%2<D1H%!/X5-110`54DTO3II&DEL+:1V.69H5)/XXJW10!7@T^RM7+V]G
M!"Y&"T<84X_`58HHH`KSV%E=.'N+2"9@,!I(PQ`_&DATVQMI!+!96\3CHR1*
MI_,"K-%`!2$`C!&0:6B@"E_8VE_]`VT_[\+_`(5:AABMXA%#&D4:]$10`/P%
M/HH`*AN+2VNPHN;>*8+T$B!L?G4U%`%6+2]/AD62*PMHW7D,L*@C\<5:HHH`
M;)&DJ%)$5T;@JPR#63<>$?#=VVZXT'3I&]6M4_PK8HH`PX_!7A:)MR>'=,5A
MW%JG^%:UM:6UFFRUMXH$_NQ(%'Z5-10`5!<6-I=E3<VL,Q7@&2,-C\ZGHH`J
MQ:9I]O()8;&VBD7HR1*"/Q`JU110`4444`1SV\%S'Y=Q#',F<[9%##\C5;^Q
M]+_Z!MI_WX7_``J[10!5FTVPN)#)/8V\KG@L\2D_F11%I>GP2+)%86T;KR&2
M%01^.*M44`%%%%`%:;3K&YD,D]E;RN>-SQ*Q_,BFQZ5IT4BR1V%JCJ<JRPJ"
-#['%6Z*`"BBB@#__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
